CNVVY (ConvaTec Group) Total Liabilities : $1,826 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is ConvaTec Group Total Liabilities?

ConvaTec Group's Total Liabilities for the quarter that ended in Dec. 2024 was $1,826 Mil.

ConvaTec Group's quarterly Total Liabilities declined from Dec. 2023 ($2,021.00 Mil) to Jun. 2024 ($1,969.40 Mil) and declined from Jun. 2024 ($1,969.40 Mil) to Dec. 2024 ($1,826.10 Mil).

ConvaTec Group's annual Total Liabilities increased from Dec. 2022 ($1,982.30 Mil) to Dec. 2023 ($2,021.00 Mil) but then declined from Dec. 2023 ($2,021.00 Mil) to Dec. 2024 ($1,826.10 Mil).

ConvaTec Group Total Liabilities Historical Data

The historical data trend for ConvaTec Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ConvaTec Group Total Liabilities Chart

ConvaTec Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

2,095.80

1,979.20

1,982.30

2,021.00

1,826.10

ConvaTec Group Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															1,982.30	2,127.00	2,021.00	1,969.40	1,826.10

ConvaTec Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ConvaTec Group's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	512.3	+	(1179.6	+	101.5
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	15.7	+	17)
	=	1,826

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	3515	-	1688.9
	=	1,826

ConvaTec Group's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	512.3	+	(1179.6	+	101.5
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	15.7	+	17)
	=	1,826

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	3515	-	1688.9
	=	1,826

ConvaTec Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of ConvaTec Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

ConvaTec Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ConvaTec Group PLC (OTCPK:CNVVY) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CNVVF:USA CTECl:UK CTEC:UK 2CV:Germany

Address

20 Eastbourne Terrace, 7th Floor, Paddington, London, GBR, W2 6LG

Website

https://www.convatecgroup.com

Originally spun out of Bristol-Myers Squibb, ConvaTec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.